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Little is known about how DNA damage and metabolism are interconnected. In this issue of Cancer Cell,
Jeong and colleagues report that an important component of the DNA damage response is the SIRT4-
mediated blockade of glutamine catabolism. Failure to shut down glutamine consumption results in
unscheduled proliferation, genomic instability, and cancer.DNA damage is a natural process that
occurs in all cells under normal physiolog-
ical conditions. Multiple cellular mecha-
nisms sense thepresenceofDNAdamage
and trigger adaptive responses (collec-
tively known as DNA damage response
or DDR), which culminate in a proliferative
arrest that allows for DNA repair. Defects
in the DDR can lead to unrepaired DNA
damage, including oncogenic DNA alter-
ations, and eventually to cancer. In recent
years, it has become evident that cell
proliferation and metabolism are inti-
mately connected (DeBerardinis et al.,
2008), therefore implying that DDR-
induced proliferative arrest must be
accompanied by metabolic changes.
However, although much is known about
the molecular biology of the DDR, the
metabolic consequences of DNA damage
have remained largely unexplored until
very recently. The DDR has been shown
to increase the cellular antioxidant de-
fenses through the production of NADPH
by the pentose phosphate pathway (Ben-
saadet al., 2006;Cosentinoet al., 2011). In
other settings, the DDR downregulates
glucose uptake and glycolysis (Zhou
et al., 2002). These precedents support
the concept that metabolic changes
constitute an intrinsic aspect of the DDR.
A new study by Jeong et al. (2013) in
this issue of Cancer Cell uncovers a new
connection between the DDR and meta-
bolism. By performingmetabolic analyses
of cells in the presence or absence of DNA
damage, the authors confirmed previous
reports indicating that DNA damage
increases the flux through the pentose
phosphate pathway (Bensaad et al.,
2006; Cosentino et al., 2011). In addition,
they found an unexpected decrease in
glutamine uptake and in intermediates of
the tricarboxylic acid (TCA) cycle. These
initial observations set the focus on theconnection between DNA damage, gluta-
mine, and the TCA cycle.
Quiescent cells use the TCA cycle
to produce energy from glucose. In
contrast, proliferating cells mostly use it
for a completely different purpose: as a
carbon source for lipogenesis through
the mitochondrial efflux of citric acid.
This efflux must be compensated by an
influx of TCA cycle intermediates, a pro-
cess known as anaplerosis. Of relevance,
glutamine is the main source for TCA
anaplerosis in proliferating cells (DeBerar-
dinis et al., 2008). In a first reaction, gluta-
mine is converted into glutamate by
glutaminase (GLS) and then into a-keto-
glutarate (aKG) by either glutamate dehy-
drogenase (GDH) or, less prominently, by
transamination-coupled reactions. Jeong
et al. (2013) characterize how several
types of DNA damage block glutamine
anaplerosis in proliferating cells. They
had previously shown that SIRT4 ADP-
ribosylates and inhibits GDH (Haigis
et al., 2006), and based on this, they
reasoned that SIRT4 might be involved
in the inhibition of glutamine uptake and
anaplerosis triggered by DNA damage.
SIRT4 is a member of the sirtuin family
(SIRT1–7) of protein deacetylases and
ADP-ribosylases involved in multiple
cellular processes, including the mainte-
nance of genomic stability and regulation
of metabolism (Sebastia´n et al., 2012).
Interestingly, SIRT4 mRNA levels were
highly induced upon different types of
DNA damage, even higher than other
sirtuin members previously related to the
DDR, such as SIRT1 or SIRT3. Impor-
tantly, the authors demonstrate that
SIRT4-mediated inhibition of glutamine
anaplerosis is necessary for efficient cell
cycle arrest upon DNA damage (Figure 1).
In the absence of SIRT4, failure to arrest
the cell cycle in response to DNA damageCancer Celresults in delayed DNA repair and
increased chromosomal aneuploidies.
Even more, SIRT4-deficient primary
fibroblasts already show aberrant levels
of polyploidy, suggesting that SIRT4 is
important not only in response to exoge-
nously inflicted DNA damage, but also to
protect cells from spontaneous damage.
The above findings suggest that the
SIRT4-mediated blockade of glutamine
anaplerosis could be a tumor suppressor
mechanism. Indeed, Jeong et al. (2013)
present multiple lines of evidence. First,
they show that SIRT4-deficient fibroblasts
grow faster than their wild-type counter-
parts. Also, neoplastic SIRT4-deficient
fibroblasts are less dependent on glucose
and form larger allograft tumors than
SIRT4-proficient cells. These pro-tumori-
genic phenotypes were reversed when
cells were treated with GLS1 or GDH
inhibitors or upon ectopic expression of
catalytically active, but not catalytically
dead, SIRT4. Moreover, several human
malignancies present reduced SIRT4
mRNA levels, and this is associated with
a poorer outcome in the case of lung
adenocarcinomas.
The authors recapitulate their main
findings in genetically modified mice
lacking SIRT4 (Jeong et al., 2013). Impor-
tantly, two independently generated
strains of SIRT4-deficient mice present a
significant incidence of spontaneous
lung tumors compared to their wild-type
littermates. In support of a direct inhibitory
effect of SIRT4 on GDH (Haigis et al.,
2006), lung extracts from SIRT4-deficient
mice presented higher constitutive levels
of GDH activity. Moreover, ionizing
irradiation decreased GDH activity in
wild-type but not SIRT4-deficient lungs.
Together, these observations compel-
lingly demonstrate that SIRT4 is a tumor
suppressor contributing to the DDR byl 23, April 15, 2013 ª2013 Elsevier Inc. 427
Figure 1. SIRT4: The Glutamine Gatekeeper
DNA damage (1) elicits the DDR (2) that, through undefined mechanisms (indicated with a question mark),
results in enhanced SIRT4 transcription (3) and higher SIRT4 activity in the mitochondria (4). In turn, SIRT4
inhibits glutamine conversion into aKG by inhibiting glutamate dehydrogenase (GDH) (5). Decreased aKG
shuts down the anaplerotic replenishment of the tricarboxylic acid cycle (TCA) (6), which, through mech-
anisms that remain to be clarified (question mark), result in arrest and DNA repair (7).
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The new findings by Jeong et al. (2013)
strongly reinforce previous evidences
pointing to glutamine-dependent anaple-
rosis as an attractive Achilles’ heel of
cancer cells. For example, GLS1 inhibition
impairs neoplastic transformation (Wang
et al., 2010). Also, estrogen receptor-
negative breast cancers present a
particular type of glutamine-dependent
anaplerosis characterized by elevated
levels of the gene encoding phosphoglyc-
erate dehydrogenase (PHGDH) (Posse-
mato et al., 2011). This enzyme diverts
phosphoglycerate (a glycolytic intermedi-
ate) into the so-called serine pathway.
The relevance of this pathway for cancer
does not reside in the synthesis of serine
but on the fact that its transamination
step is coupled to the conversion of gluta-
mate into aKG, thereby directly contrib-
uting to TCA anaplerosis independently
of GDH (Possemato et al., 2011). Impor-
tantly, inhibition of PHGDH in breast can-
cer cell lines induces ametabolic collapse
in TCA cycle intermediates that is highly428 Cancer Cell 23, April 15, 2013 ª2013 Elsreminiscent to the one observed upon
DDR-induced SIRT4 upregulation and
the ensuing GDH inhibition (Jeong et al.,
2013; Possemato et al., 2011).
A few aspects in the DDR-mediated
block in glutamine anaplerosis still remain
to be elucidated. Not much is known
about the mechanisms that upregulate
SIRT4 mRNA by DNA damage, apart
from the lack of involvement of p53
(Jeong et al., 2013). Finding the exact
components of the DDR pathway respon-
sible for SIRT4 induction could point to
new strategies to shut down glutamine-
dependent anaplerosis. It is also unclear
yet how the glutamine-dependent ana-
plerotic blockade contributes to the im-
plementation of DDR-induced cell cycle
arrest.
Intriguingly, with the current report,
essentially all members of the sirtuin
family have been involved in cancer pro-
tection and metabolism (Sebastia´n et al.,
2012). The fact that sirtuin activity
depends on the intracellular levels of the
co-substrate NAD+ opens the possibility
that enhancing NAD+ biosynthetic path-evier Inc.ways could result in a general activation
of sirtuins and a concurrent enhancement
of tumor suppression. As a proof of princi-
ple, treatingmicewith anNAD+ precursor,
nicotinamide riboside, activates at least
SIRT1 and SIRT3, improves energy
expenditure and fatty acid oxidation, and
protects mice from diet-induced obesity
and metabolic syndrome (Canto´ et al.,
2012). How these metabolic effects will
apply to a cancer scenario is not clear
yet, but the increasing body of evidence
suggests that global sirtuin activation will
protect against cancer.
In summary, the current paper together
with previous evidences reinforces two
parallel strategies for treating cancer: (1)
SIRT4 activation either through specific
approaches or through a general activa-
tion of sirtuins, and (2) inhibition of gluta-
mine-dependent anaplerosis through
inhibition of GLS, GDH, or even PHGDH.REFERENCES
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